SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 Zai Lab Limited today announced that the Center for Drug Evaluation of the National Medical Products Administration granted Breakthrough.
Study met primary endpoint ; VYVGART® Hytrulo demonstrated 61% reduction in risk of relapse versus placebo IgG autoantibodies shown to play significant role in underlying CIDP disease biology.
Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG.
SHANGHAI, China and CAMBRIDGE, Mass., July 10, 2023 Zai Lab Limited today announced that China’s National Medical Products Administration has accepted the Biologics License Application .
Mirae Asset Global Investments Co. Ltd. grew its stake in Zai Lab Limited (NASDAQ:ZLAB – Get Rating) by 1.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 173,361 shares of the company’s stock after acquiring an additional 2,240 shares during the quarter. Mirae […]